Diminished Expression of CRHR2 in Human Colon Cancer Promotes Tumor Growth and EMT Via Persistent IL-6/Stat3 Signaling

Overview

Journal Cell Mol Gastroenterol Hepatol

Specialty Gastroenterology

Date 2015 Oct 24

PMID 26495412

Citations 28

Authors

Jorge A Rodriguez

Sara Huerta-Yepez

Ivy Ka Man Law

Guillermina J Baay-Guzman

Belen Tirado-Rodriguez

Jill M Hoffman

Dimitrios Iliopoulos

Daniel W Hommes

Hein W Verspaget

Lin Chang

Charalabos Pothoulakis

Stavroula Baritaki

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Chronic inflammation promotes development and progression of colorectal cancer (CRC). We explored the distribution of Corticotropin-Releasing-Hormone (CRH)-family of receptors and ligands in CRC and their contribution in tumor growth and oncogenic EMT.

Methods: mRNA expression of CRH-family members was analyzed in CRC (N=56) and control (N=46) samples, 7 CRC cell lines and normal NCM460 cells. Immunohistochemical detection of CRHR2 was performed in 20 CRC and 5 normal tissues. Cell proliferation, migration and invasion were compared between Urocortin-2 (Ucn2)-stimulated parental and CRHR2-overexpressing (CRHR2+) cells in absence or presence of IL-6. CRHR2/Ucn2-targeted effects on tumor growth and EMT were validated in SW620-xenograft mouse models.

Results: CRC tissues and cell lines showed decreased mRNA and protein CRHR2 expression compared to controls and NCM460, respectively. The opposite trend was shown for Ucn2. CRHR2/Ucn2 signaling inhibited cell proliferation, migration, invasion and colony formation in CRC-CRHR2+ cells. , SW620-CRHR2+ xenografts showed decreased growth, reduced expression of EMT-inducers and elevated levels of EMT-suppressors. IL-1b, IL-6 and IL-6R mRNAs where diminished in CRC-CRHR2+ cells, while CRHR2/Ucn2 signaling inhibited IL-6-mediated Stat3 activation, invasion, migration and expression of downstream targets acting as cell cycle- and EMT-inducers. Expression of cell cycle- and EMT-suppressors was augmented in IL-6/Ucn2-stimulated CRHR2+ cells. In patients, CRHR2 mRNA expression was inversely correlated with IL-6R and vimentin levels and metastasis occurrence, while positively associated with E-cadherin expression and overall survival.

Conclusions: CRHR2 downregulation in CRC supports tumor expansion and spread through maintaining persistent inflammation and constitutive Stat3 activation. CRHR2 CRC phenotypes are associated with higher risk for distant metastases and poor clinical outcomes.

Citing Articles

Identification of AKNA Gene and Its Role for Genetic Susceptibility in Epithelial Ovarian Cancer.

Suryandari D, Miftahuzzakiyah M, Yunaini L, Kodariah R, Sukmawati D, Rustamadji P Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996799 PMC: 11854646. DOI: 10.3390/cimb47020078.

IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.

Oyende Y, Taus L, Fatatis A Cancers (Basel). 2025; 17(2).

PMID: 39858071 PMC: 11763358. DOI: 10.3390/cancers17020290.

Role of CRH in colitis and colitis-associated cancer: a combinative result of central and peripheral effects?.

Zhu C, Li S Front Endocrinol (Lausanne). 2024; 15:1363748.

PMID: 38616821 PMC: 11010637. DOI: 10.3389/fendo.2024.1363748.

Contemporaneous Perioperative Inflammatory and Angiogenic Cytokine Profiles of Surgical Breast, Colorectal, and Prostate Cancer Patients: Clinical Implications.

Baghaie L, Haxho F, Leroy F, Lewis B, Wawer A, Minhas S Cells. 2023; 12(23).

PMID: 38067195 PMC: 10706122. DOI: 10.3390/cells12232767.

RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer.

Ma Z, Sun Q, Zhang C, Zheng Q, Liu Y, Xu H Int J Biol Sci. 2023; 19(14):4411-4426.

PMID: 37781036 PMC: 10535698. DOI: 10.7150/ijbs.81972.

References

Joyce T, Cantarella D, Isella C, Medico E, Pintzas A . A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis. 2009; 26(6):569-87. DOI: 10.1007/s10585-009-9256-9. View

OConnor D, Grossman D, Plescia J, Li F, Zhang H, Villa A . Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000; 97(24):13103-7. PMC: 27185. DOI: 10.1073/pnas.240390697. View

Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk M, Merseburger A . The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate. 2008; 69(4):443-8. DOI: 10.1002/pros.20892. View

Wei D, Le X, Zheng L, Wang L, Frey J, Gao A . Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003; 22(3):319-29. DOI: 10.1038/sj.onc.1206122. View

Chang J, Hoy J, Idumalla P, Clifton M, Pecoraro N, Bhargava A . Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis. Peptides. 2007; 28(7):1453-60. PMC: 3718314. DOI: 10.1016/j.peptides.2007.05.008. View

Jin L, Li C, Li R, Sun Z, Fang X, Li S . Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A₂ and migration in prostate cancer cell RM-1. J Mol Endocrinol. 2014; 52(3):255-67. DOI: 10.1530/JME-13-0270. View

Ciocca D, Puy L, Fasoli L, Tello O, Aznar J, Gago F . Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990; 15(3):175-84. DOI: 10.1007/BF01806354. View

Spano J, Milano G, Rixe C, Fagard R . JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer. 2006; 42(16):2668-70. DOI: 10.1016/j.ejca.2006.07.006. View

Mueller M, Fusenig N . Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4(11):839-49. DOI: 10.1038/nrc1477. View

10.

Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G . Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest. 2008; 26(4):359-68. DOI: 10.1080/07357900701788106. View

11.

Gay J, Kokkotou E, OBrien M, Pothoulakis C, Karalis K . Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis. Endocrinology. 2008; 149(7):3403-9. PMC: 2453096. DOI: 10.1210/en.2007-1703. View

12.

Chatzaki E, Lambropoulou M, Constantinidis T, Papadopoulos N, Tache Y, Minopoulos G . Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis. J Cell Physiol. 2006; 209(3):905-11. DOI: 10.1002/jcp.20792. View

13.

Chen C, Cen L, Kohout J, Hutzen B, Chan C, Hsieh F . Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008; 7:78. PMC: 2577686. DOI: 10.1186/1476-4598-7-78. View

14.

Terzic J, Grivennikov S, Karin E, Karin M . Inflammation and colon cancer. Gastroenterology. 2010; 138(6):2101-2114.e5. DOI: 10.1053/j.gastro.2010.01.058. View

15.

Tanaka T . Animal models of carcinogenesis in inflamed colorectum: potential use in chemoprevention study. Curr Drug Targets. 2012; 13(14):1689-97. DOI: 10.2174/138945012804545452. View

16.

Baritaki S, Chapman A, Yeung K, Spandidos D, Palladino M, Bonavida B . Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009; 28(40):3573-85. DOI: 10.1038/onc.2009.214. View

17.

Reubi J, Waser B, Vale W, Rivier J . Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab. 2003; 88(7):3312-20. DOI: 10.1210/jc.2002-021853. View

18.

Niu G, Wright K, Ma Y, Wright G, Huang M, Irby R . Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005; 25(17):7432-40. PMC: 1190305. DOI: 10.1128/MCB.25.17.7432-7440.2005. View

19.

Lopez-Novoa J, Nieto M . Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2010; 1(6-7):303-14. PMC: 3378143. DOI: 10.1002/emmm.200900043. View

20.

Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M . Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology. 2006; 148(4):1524-38. DOI: 10.1210/en.2006-0967. View